Background The COVID-19 pandemic which started in November 2019 and since then has led to multiple lockdowns aimed towards controlling the pandemic, these lockdowns contributed to major changes in individuals’ lifestyles including eating patterns and restriction of physical activity due to continues house confinement. Such changes have significantly contributed to weight change, with increasing rates of obesity in the UAE, COVID-19 have posed a major concern to the country’s obesity levels. Aim To measure the prevalence and investigate the views related to weight change among adults in the UAE during the COVID-19 pandemic. Methods A cross-sectional study was conducted through a self-administered online questionnaire distributed using social media platforms between February 15th and March 14th, 2021. The sample size was 439 adults in the UAE (18–59 years), collected by volunteer sampling. Analysis was done using SPSS with a significance of 5.0%. Exclusion criteria included pregnancy and bariatric surgeries history. Results 51.1% of participants gained weight, 36.2% lost weight and 12.7% maintained their weight. Meal consumption frequency and weight gain were correlated. Consuming fast food resulted in 65.7% of participants gaining weight. 66.2% of people who lost weight during the COVID-19 pandemic did exercise. Stress management and sleeping patterns were not contributing factors to the weight change. 64.4% of the participants who were not satisfied with their weight and believed that they need to make changes in their lifestyle received no guidance from professional personnel to reach their desired weight. Conclusion In this study, the majority of participants have witnessed an increase in weight. UAE health authorities must provide guidance and support to the population via structured nutritional programs and lifestyle awareness campaigns.

There has been a substantial increase in the use of extracorporeal membrane oxygenation (ECMO) support in critically ill adults. Understanding the complex changes that could affect drugs’ pharmacokinetics (PK) and pharmacodynamics (PD) is of suitable need. Therefore, critically ill patients on ECMO represent a challenging clinical situation to manage pharmacotherapy. Thus, clinicians’ ability to predict PK and PD alterations within this complex clinical context is fundamental to ensure further optimal and, sometimes, individualized therapeutic plans that balance clinical outcomes with the minimum drug adverse events. Although ECMO remains an irreplaceable extracorporeal technology, and despite the resurgence in its use for respiratory and cardiac failures, especially in the era of the COVID-19 pandemic, scarce data exist on both its effect on the most commonly used drugs and their relative management to achieve the best therapeutic outcomes. The goal of this review is to provide key information about some evidence-based PK alterations of the drugs used in an ECMO setting and their monitoring.